| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 134.46 | 57.5% | 7.7% |
| Total Income | 135.35 | 47.5% | 3.5% |
| Expenditure | 137.26 | 24.3% | 9.2% |
| PBT | -1.91 | 89.8% | 138.1% |
| Net Profit | -4.10 | 76.6% | 191.4% |
| OPM | 5.79% | 23.30pp | 0.34pp |
| NPM | -3.03% | 16.11pp | 6.46pp |
| EPS | -1.76 | 121.3% | 168.5% |
Order Book Surges, But Execution Lags Target; Margin Recovery Pushed to FY28
Concord's ₹714 Cr order book (+34% YoY) is real and growing, but Q2's 7.7% revenue growth falls sharply below the 15-20% FY27 target management reaffirmed. The ₹4.1 Cr net loss despite 57.5% gross margins signals a company in an investment phase—with visibility ahead, but execution risk that the market is pricing in heavily.
₹134.5 Cr
+7.7% YoY
₹714 Cr
+34% YoY
–₹4.1 Cr
vs profit YoY
57.5%
+500 bps YoY
Concord Enviro's Q2 result is a study in mismatch. The headline—a ₹4.1 Cr net loss despite ₹134.5 Cr in revenue and a 57.5% gross margin—masks an underlying story that the market has already priced in steeply: the company is investing its way toward capacity expansion, and near-term profitability is being deferred in pursuit of that goal. The order book has surged 34% YoY to ₹714 Cr, and management reaffirmed a 15-20% FY27 revenue growth target. Yet Q2 delivered only 7.7% growth—a pace that, if sustained, will not meet that guidance. Management attributes the shortfall to supply-chain headwinds and project lumpiness, both of which are real; but the gap also reflects execution velocity that has lagged the ramp needed.
The profit waterfall: where the loss came from
Gross profit expanded meaningfully to ₹77.3 Cr (57.5% margin, +500 bps YoY), but EBITDA compressed to ₹7.78 Cr (5.8% margin, down 30 bps YoY) and fell into a ₹4.1 Cr net loss. The culprits: fixed-cost absorption from the capex cycle (Vasai facility ramp, Sharjah rebalancing), forex losses on Mexican peso exposure, and investment spend in talent and new product development. Management characterized this as a temporary phase; by FY28, operating leverage and fixed-cost absorption should lift EBITDA margins to low double digits (10-12%), progressing toward the long-term 14-15% target by FY29. That timeline is credible given the order book and the nascent nature of new products (H-Xtreme, zero liquid discharge, compressed biogas), but it is no longer near-term.
Claims on the call vs. what holds up
Order book 34% growth YoY to ₹714 Cr
Confirmed: ₹714 Cr vs ₹533 Cr prior year
Supported
Gross margin 57.5% (up 500 bps YoY)
Confirmed: ₹77.3 Cr gross profit on ₹134.5 Cr revenue
Supported
15-20% FY27 revenue growth expected
Q2 delivered 7.7% YoY; annualized H2 pace would need to exceed 20% to meet guidance. At current trajectory, FY27 growth is tracking 12-15% range, not upper-end guidance.
Overstated
EBITDA margins to reach double digits by FY28
Q2 EBITDA margin 5.8% vs 6.1% prior year; margin declined despite gross margin expansion. Management conceded FY28 will deliver 'low double digits,' not high. Recovery timeline realistic but extended.
Slightly overstated
Strong order flow; expect ₹500-600 Cr order intake next 6 months
Visible: ₹126 Cr steel project (Q4 delivery start), ₹14.25 Cr solar order (post-Q2), ₹3,000 Cr bid pipeline. Conversion at 15-20% is plausible but not yet confirmed.
Plausible, unconfirmed
What changed from the prior call
Order book upgraded: +34% YoY momentum; domestic order intake +55% H1 suggests structural shift toward larger, more complex projects
Margin timeline downgraded: Prior long-term target was 14-16% EBITDA. Now sequenced as low double digits (10-12%) by FY28, then 14-15% by FY29.
Revenue guidance reiterated but not hitting the Q2 pace needed: 15-20% FY27 remains the call, but Q2 execution (7.7% YoY) signals unmet timing.
New products gaining validation: H-Xtreme heat exchanger orders in hand; CBG partnership with Waffa active; ZLD and membrane for data centers in bid phase.
The street's view: price, ownership, volume
The stock trades at ₹227.2, down 73.6% from its all-time high of ₹860, and is trading below its 20-, 50-, and 200-day moving averages (SMA20 ₹236.41, SMA50 ₹254.19, SMA200 ₹296.07). Volume is increasing, a signal of distribution rather than accumulation. Ownership shows FII exiting: foreign institutional holdings fell 91 basis points quarter-on-quarter to just 0.37%, the lowest on record in this dataset. Domestic institutional interest is stable but low (7.21%). Promoters hold steady at 51.43%. This ownership shift—FII flight amid rising volume—suggests the market is repricing the execution risk and timeline extension evident in the fundamentals. The drawdown from ATH is severe, but the question is not whether the stock is cheap on a price basis; it is whether the company can deliver on the new timeline it articulated on this call.
The bull-bear ledger
Order book ₹714 Cr (+34% YoY) with ₹3,000 Cr bid pipeline provides multi-quarter revenue visibility
Gross margin 57.5% (+500 bps) confirms pricing power and product mix improvement
Domestic order momentum (+55% H1) shows market acceptance; O&M segment (40% of revenue) has steady 12-month visibility
Capacity expansion (Vasai ramped, Sharjah rebalanced) is a one-time capex cycle; fixed-cost drag should ease by FY28
New products in early traction (H-Xtreme orders booked; CBG partnership progressing; ZLD/membrane data-center bids underway)
Q2 net loss ₹4.1 Cr and EBITDA margin down YoY (5.8% vs 6.1%) despite gross margin expansion signals execution friction
Revenue growth 7.7% YoY falls sharply below 15-20% FY27 target; required H2 pace is not being hit
Margin recovery deferred to FY28-29; near-term profitability sub-par despite order visibility
Execution risk on new product scaling (ZLD, CBG, H-Xtreme, membrane) is unproven; design and project teams being built
FII exiting (down to 0.37%); stock 73% below ATH; valuation repricing ongoing
Risks, ranked by holder concern
1
HighRevenue growth shortfall / execution slippage on large orders
Q2 delivered 7.7% YoY growth; to hit 15% FY27 growth, H2 must annualize 20%+. The ₹126 Cr steel project (14-18 month lead, Q4 delivery start) and ₹14.25 Cr solar order (post-Q2) are visible, but lumpiness in large-order execution is proven risk. If these orders slip, FY27 guidance misses.
2
HighFixed-cost absorption timeline extends beyond FY28
Capex cycle (Vasai, Sharjah, talent) is front-loaded. If order-book-to-revenue conversion is lumpy or if new products (ZLD, CBG, H-Xtreme, data center) monetize slower than expected, fixed-cost drag persists beyond FY28, deferring double-digit EBITDA margins further into FY29.
3
MediumGeopolitical / supply-chain headwinds persist
GCC region (32% of Q2 export revenue) experienced delays in Q1-Q2. Middle East tensions, USD-MXN forex volatility, and freight rate swings remain. If these headwinds resurface, gross margins could compress and project delivery timelines extend.
4
MediumNew product adoption slower than guided
H-Xtreme, CBG, ZLD, and membrane-based data-center solutions are all in early validation or bid phase. If monetization is slower or customer adoption more cautious, the long-term margin bridge (14-15% by FY29) loses its near-term stepping stone.
5
LowWorking capital cycle deterioration
Inventory/receivables at 110-120 days (target 140-150). If project execution becomes more complex or payment terms slacken, cash outflows spike, pressuring liquidity during the capex cycle.
The debate
1 · Q3 revenue trajectory (execution pace)
Is H2 accelerating toward the 15-20% FY27 pace, or are large orders still lumpy and slipping? The ₹126 Cr steel project should be ramping for Q4 delivery; early wins in Q3 would validate the FY27 growth guidance. A miss here suggests the timeline is slipping.
2 · EBITDA margin floor and recovery timing
Does Q3 EBITDA margin hold above 5.8%, or does it compress further? If it dips, the capex cycle drag is deeper than expected. If it holds or expands slightly, it suggests fixed-cost absorption is beginning and double-digit FY28 margins are on track.
3 · New product monetization (H-Xtreme, CBG, ZLD, data center)
Are there wins beyond current visibility? H-Xtreme orders are 'booked,' but CBG and data-center opportunities are still in bid phase. Q3-Q4 updates on contract awards or design validations would signal whether the new product bridge to 14-15% margins is real.
Concord Enviro's Q2 result is not a breakout, nor is it a collapse. It is a company managing a capacity transition—investing near-term profitability for long-term scale. The order book is real, the gross margins are real, and the market for environmental water treatment is structural. But execution velocity has not matched the ramp management guided to, and the market has priced that in steeply. The stock is down 73% from ATH, FII is exiting, and the outlook hinges on whether H2 accelerates to meet guidance or slips further. Holders should view the next 2-3 quarters as the make-or-break test for the 15-20% FY27 growth thesis and the margin recovery timeline. Until Q3 data points to acceleration, the risk/reward remains balanced at best, bearish at worst.
The number to track from here: FY27 revenue run-rate. If H2 annualizes above 18% YoY growth, the guidance is back on track and the capex cycle is justified. If it remains below 12% YoY, the timeline is slipping and margin recovery is being deferred further.
Strong order book masks weak Q2 execution; margin expansion deferred
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Q1 missed due to supply chain; Q2 shows slight recovery but well below prior-year growth pace and margin expectations.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Concord Enviro is executing a capacity-building transition with a robust order book (₹714 Cr, +34% YoY) and healthy gross margins (57.5%), but Q2's 7.7% revenue growth and ₹4.1 Cr net loss fall sharply below the 15-20% FY27 target needed to justify current margins and investor confidence. Execution risk on new product lines (ZLD, CBG, membrane for data centers) remains high.
₹134.5 Cr
Revenue · +7.7% YoY₹-4.1 Cr
Reported PAT · −191.4% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Order book 34% growth YoY to ₹714 Cr
METDelivered ₹714 Cr; represents 34% YoY growth as stated
Gross margin improved to 57.5% from 50.5% YoY
METGross profit INR 772.67M vs INR 629.93M; 57.5% vs 50.5% confirmed
15%-20% FY27 revenue growth expected
OVERSTATEDQ2 shows 7.7% YoY growth; far below needed 15-20% annualized pace
EBITDA will reach double digits by FY28
OVERSTATEDQ2 EBITDA margin 5.8% vs 6.1% prior year; margin compression ongoing
Strong demand across steel, solar, chemicals, pharma
METOrder book strong at ₹714 Cr; ₹14.25 Cr solar order post-Q2; ₹126 Cr steel project confirmed
Domestic revenue 68% of Q2; export 32%
METAs stated by management; order intake domestic up 55% vs H1 prior year
Earnings quality
What changed since the last call
Margin recovery timeline extended
DowngradePrior: 14-16% EBITDA deferred to ₹850 Cr revenue. Now: 10%-12% double digits only by FY28; full target by FY29
Order book momentum intact
Upgrade₹714 Cr order book +34% YoY; ₹3,000 Cr bidding pipeline; domestic order intake +55% H1 vs prior year
Quarterly revenue volatility acknowledged
NeutralQ3-Q4 will be lumpy; H2 expected to recover but Q-o-Q swings to continue based on large-order execution timing
The Q&A
Analysts pressed hard on margin timeline (Nishita Sapphire, Harshash Saraswat) and execution confidence (Dilip Sahu); management held firm on 14-15% by FY29 but conceded FY28 low double-digits, showing transparency but some defensive framing around capex and investment costs.
Quarterly volatility — Shaishav Vora, Prudent Investments
AnsweredH2 heavy, H3-H4 suppressed (industry trend). Mix of normal vs large orders (>₹50 Cr) creates lumpiness. Q3-Q4 sees pickup.
FY27 revenue path — Nishita, Sapphire Capital
AnsweredYes, we have large orders executing in Q4 for steel; confident Q3-Q4 will meet growth expectation and ₹714 Cr order book visibility
Margin recovery timeline — Nishita, Sapphire Capital
PartialFY28 low double-digits (10%-12%); FY29 onwards 14%-15% as operating leverage kicks in. Investments in talent & tech will pay off.
Sharjah capacity & competition — Henil Bagadia, Equiscorp
AnsweredCurrently 50-60%; recalibrated for cost structure. Membrane offering differentiated (lower OpEx vs Chinese generics); long-term value in specialized products.
Order intake & bidding — Giriraj Daga, Visaria Family Office
Answered₹500-600 Cr expected order intake. Conversions typically 15-20%; mix of short (executed quickly) and long-lead projects.
FY27 EBITDA margin expectations — Harshash Saraswat, Srujan Alpha
PartialBy FY28, double digits expected. Growth is 20%-25% annual; margins will stable once project execution improves & GCC supply normalizes.
Data center market opportunity — Deeraj Ram, 360 ONE Capital
PartialYes, actively bidding. Dehumidification & water requirements for data centers emerging. No specific order yet but combination of membrane + dehumidification products will unlock value.
O&M business scaling — Raj Shah, individual investor
AnsweredO&M is 40% of revenues, steady 12-month visibility. Mixed margins (O&M ~20%, S&P projects lumpy). Growth will accelerate as installed base increases.
Guidance
FY27: 15-20% annual revenue growth (₹782-816 Cr implied from ₹680 Cr+ H1 base)
MediumAssumes ₹500-600 Cr order intake next 6 months; large orders (steel, solar) visible; execution risk on supply chain normalization
FY28+: 20-25% annual CAGR over next 3-5 years
MediumDriven by new product scaling (ZLD, membrane, CBG, H-Xtreme, data center solutions) and domestic order book momentum
FY27: EBITDA margins remain under pressure (low single digits); comparable to FY26
HighFixed-cost absorption ongoing; ₹30-35 Cr capex this year for capacity expansion; margins to stabilize by Q4
FY28: Double-digit EBITDA margins (10%-12% low double digits)
MediumOperating leverage from higher revenue, reduced fixed-cost drag; assumes successful project execution and supply-chain normalization
FY29+: Target 14%-15% EBITDA margins (long-term goal) when revenue reaches ₹850 Cr+
MediumDependent on scaling of O&M/recurring revenue (40% of total), new product adoption, and project execution improving
FY27: ₹30-35 Cr capex (Vasai facility improvements, maintenance)
HighVasai expansion completed; funded from IPO proceeds; maintenance capex INR 15-20 Cr ongoing
FY28: ₹50-60 Cr capex for Sharjah facility expansion; potential new unit for capacity enhancement
MediumSharjah scale-up decision pending geopolitical clarity; alternative unit expansion planned 4-5 years ahead
Risks the call surfaced
Execution on large orders
MediumSteel sector ₹126 Cr project (14-18 month cycle) and new product lines (ZLD, H-Xtreme, CBG, data center) in early-stage scaling; design & execution teams being built; margin pressure if ramp slower than expected
Geopolitical & supply-chain disruption
MediumGCC region impacted by Middle East tensions; delays in movement of membranes, critical components from UAE; USD-MXN forex headwinds affecting Mexico operations; 32% of Q2 revenue from export
Margin expansion delay
MediumQ2 EBITDA margin 5.8% vs 6.1% prior year; net loss ₹4.1 Cr despite revenue growth. Fixed-cost absorption from capex cycle (Vasai, Sharjah expansion) stretching margin recovery to FY28-29, not FY27.
Revenue growth shortfall
MediumQ2 delivered 7.7% YoY growth, well below 15-20% FY27 target. Order intake pipeline ₹3,000 Cr is large but conversion uncertain; execution delays in Q1 & Q2 show track record risk.
New product adoption & scaling
LowMultiple new product lines in early validation phase; H-Xtreme gaining traction; CBG progressing with Waffa partnership; ZLD & membrane for data centers still in design/bid phase. Limited near-term revenue contribution.
Management
Score 7/10. Clear on product/market specifics, order pipeline, and capacity plans. Candid on GCC headwinds, forex losses, and investment phase. Some hedging on exact margin timelines and 15-20% FY27 growth confidence. Mixed track record: Q1 execution delays due to supply chain; Q2 shows recovery but 7.7% YoY growth below expectations. Order book momentum (34% YoY) and O&M segment stability (40% revenue, steady margins) are strengths.
1 · Q3-Q4 FY27
Execution of ₹126 Cr steel order (14-18 month lead); ₹14.25 Cr solar order post-Q2; ₹3,000 Cr bid pipeline conversion
2 · Q4 FY27
Expected return to FY25 EBITDA margin levels post-supply-chain normalization
3 · FY28
Double-digit EBITDA margins (10%-12%) as fixed-cost absorption accelerates; capex ₹50-60 Cr for Sharjah expansion
Execution risk on new product lines (ZLD, CBG, membrane for data centers) remains high.